5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Up‐regulated acylglycerol kinase (AGK) expression associates with gastric cancer progression through the formation of a novel YAP1‐AGK–positive loop

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Acylglycerol kinase (AGK) uses adenosine triphosphate (ATP) and acylglycerol to generate adenosine diphosphate (ADP) and acyl‐sn‐glycerol 3‐phosphate in cells. Recent evidence has demonstrated that dysregulated AGK expression is associated with the development of various human cancers. This study investigated the effects of AGK on gastric cancer cell proliferation and carcinogenesis and explored the underlying molecular events. AGK expression was up‐regulated in gastric cancer and was associated with poor prognosis in gastric cancer patients. AGK overexpression increased gastric cancer proliferation, invasion capacity and the expression of the epithelial‐mesenchymal transition markers in vitro. Conversely, the knockdown of AGK expression reduced gastric cancer cell proliferation in vitro and in nude mouse tumour cell xenografts. Importantly, AGK expression was associated with the YAP1 expression in gastric cancer cells and tissues. YAP1 expression also transcriptionally induced AGK expression through the binding of TEAD to the AGK gene promoter. However, AGK expression inhibited the activation of the Hippo pathway proteins and induced YAP1 nuclear localization to enhance the transcription activity of YAP1/TEADs. In conclusion, the study demonstrates that AGK is not only a novel target of the Hippo‐YAP1 pathway, but that it also positively regulates YAP1 expression, thus forming a YAP1‐AGK–positive feedback loop.

          Related collections

          Most cited references36

          • Record: found
          • Abstract: found
          • Article: not found

          Global cancer statistics, 2012.

          Cancer constitutes an enormous burden on society in more and less economically developed countries alike. The occurrence of cancer is increasing because of the growth and aging of the population, as well as an increasing prevalence of established risk factors such as smoking, overweight, physical inactivity, and changing reproductive patterns associated with urbanization and economic development. Based on GLOBOCAN estimates, about 14.1 million new cancer cases and 8.2 million deaths occurred in 2012 worldwide. Over the years, the burden has shifted to less developed countries, which currently account for about 57% of cases and 65% of cancer deaths worldwide. Lung cancer is the leading cause of cancer death among males in both more and less developed countries, and has surpassed breast cancer as the leading cause of cancer death among females in more developed countries; breast cancer remains the leading cause of cancer death among females in less developed countries. Other leading causes of cancer death in more developed countries include colorectal cancer among males and females and prostate cancer among males. In less developed countries, liver and stomach cancer among males and cervical cancer among females are also leading causes of cancer death. Although incidence rates for all cancers combined are nearly twice as high in more developed than in less developed countries in both males and females, mortality rates are only 8% to 15% higher in more developed countries. This disparity reflects regional differences in the mix of cancers, which is affected by risk factors and detection practices, and/or the availability of treatment. Risk factors associated with the leading causes of cancer death include tobacco use (lung, colorectal, stomach, and liver cancer), overweight/obesity and physical inactivity (breast and colorectal cancer), and infection (liver, stomach, and cervical cancer). A substantial portion of cancer cases and deaths could be prevented by broadly applying effective prevention measures, such as tobacco control, vaccination, and the use of early detection tests. © 2015 American Cancer Society.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM.

            The American Joint Committee on Cancer and the International Union for Cancer Control update the tumor-node-metastasis (TNM) cancer staging system periodically. The most recent revision is the 7th edition, effective for cancers diagnosed on or after January 1, 2010. This editorial summarizes the background of the current revision and outlines the major issues revised. Most notable are the marked increase in the use of international datasets for more highly evidenced-based changes in staging, and the enhanced use of nonanatomic prognostic factors in defining the stage grouping. The future of cancer staging lies in the use of enhanced registry data standards to support personalization of cancer care through cancer outcome prediction models and nomograms.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP.

              The Drosophila TEAD ortholog Scalloped is required for Yki-mediated overgrowth but is largely dispensable for normal tissue growth, suggesting that its mammalian counterpart may be exploited for selective inhibition of oncogenic growth driven by YAP hyperactivation. Here we test this hypothesis genetically and pharmacologically. We show that a dominant-negative TEAD molecule does not perturb normal liver growth but potently suppresses hepatomegaly/tumorigenesis resulting from YAP overexpression or Neurofibromin 2 (NF2)/Merlin inactivation. We further identify verteporfin as a small molecule that inhibits TEAD-YAP association and YAP-induced liver overgrowth. These findings provide proof of principle that inhibiting TEAD-YAP interactions is a pharmacologically viable strategy against the YAP oncoprotein.
                Bookmark

                Author and article information

                Contributors
                lijunhe88@163.com
                xjxiang_nc@163.com
                lijunhe88@163.com , dengjun19871106@126.com
                Jpxiong0630@outlook.com
                Journal
                J Cell Mol Med
                J Cell Mol Med
                10.1111/(ISSN)1582-4934
                JCMM
                Journal of Cellular and Molecular Medicine
                John Wiley and Sons Inc. (Hoboken )
                1582-1838
                1582-4934
                22 August 2020
                October 2020
                : 24
                : 19 ( doiID: 10.1111/jcmm.v24.19 )
                : 11133-11145
                Affiliations
                [ 1 ] Department of Oncology The First Affiliated Hospital of Nanchang University Nanchang China
                Author notes
                [*] [* ] Correspondence

                Junhe Li, Xiaojun Xiang, Jun Deng, Jianping Xiong, Department of Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province 330006, China.

                Emails: lijunhe88@ 123456163.com (J.L); xjxiang_nc@ 123456163.com (X.X.); dengjun19871106@ 123456126.com (J.D.); Jpxiong0630@ 123456outlook.com (J.X.)

                Author information
                https://orcid.org/0000-0002-7644-5853
                https://orcid.org/0000-0003-0398-6090
                Article
                JCMM15613
                10.1111/jcmm.15613
                7576242
                32827244
                947e9c2b-771c-4f43-9ecb-89032e01df5b
                © 2020 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

                History
                : 25 October 2019
                : 20 June 2020
                : 23 June 2020
                Page count
                Figures: 6, Tables: 0, Pages: 13, Words: 7692
                Funding
                Funded by: JiangXi Province Postgraduate Special Innovation Fund
                Award ID: YC2017‐B023
                Funded by: Youth Science Foundation of Jiangxi Province , open-funder-registry 10.13039/501100010251;
                Award ID: 20171BAB215041
                Award ID: 2018ACB21037
                Funded by: Education Department of Jiangxi Province , open-funder-registry 10.13039/501100009102;
                Award ID: 700653002
                Funded by: Jiangxi Provincial Department of Science and Technology , open-funder-registry 10.13039/501100010857;
                Award ID: 20164BCD40097
                Award ID: 20171BBG70121
                Award ID: 2017BBH80027
                Funded by: National Natural Science Foundation of China , open-funder-registry 10.13039/501100001809;
                Award ID: 81660402
                Award ID: 81660405
                Award ID: 81760432
                Award ID: 81860427
                Funded by: Department of health of JiangXi Province Project
                Award ID: 20181041
                Categories
                Original Article
                Original Articles
                Custom metadata
                2.0
                October 2020
                Converter:WILEY_ML3GV2_TO_JATSPMC version:5.9.3 mode:remove_FC converted:21.10.2020

                Molecular medicine
                agk,biomarker,gastric cancer,hippo‐yap1 pathway
                Molecular medicine
                agk, biomarker, gastric cancer, hippo‐yap1 pathway

                Comments

                Comment on this article